87 related articles for article (PubMed ID: 19771429)
1. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma.
Otake AH; Mattar AL; Freitas HC; Machado CM; Nonogaki S; Fujihara CK; Zatz R; Chammas R
Cancer Chemother Pharmacol; 2010 May; 66(1):79-87. PubMed ID: 19771429
[TBL] [Abstract][Full Text] [Related]
2. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
3. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
4. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.
Arafat HA; Gong Q; Chipitsyna G; Rizvi A; Saa CT; Yeo CJ
J Am Coll Surg; 2007 May; 204(5):996-1005; discussion 1005-6. PubMed ID: 17481528
[TBL] [Abstract][Full Text] [Related]
6. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
Messadi-Laribi E; Griol-Charhbili V; Pizard A; Vincent MP; Heudes D; Meneton P; Alhenc-Gelas F; Richer C
J Pharmacol Exp Ther; 2007 Oct; 323(1):210-6. PubMed ID: 17636004
[TBL] [Abstract][Full Text] [Related]
7. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor.
Funahashi Y; Wakabayashi T; Semba T; Sonoda J; Kitoh K; Yoshimatsu K
Oncol Res; 1999; 11(7):319-29. PubMed ID: 10757446
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer.
Chen X; Meng Q; Zhao Y; Liu M; Li D; Yang Y; Sun L; Sui G; Cai L; Dong X
Cancer Lett; 2013 Jan; 328(2):318-24. PubMed ID: 23092556
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor.
Redondo-Müller MA; Stevanovic-Walker M; Barker S; Puddefoot JR; Vinson GP
Endocr Relat Cancer; 2008 Mar; 15(1):277-88. PubMed ID: 18310294
[TBL] [Abstract][Full Text] [Related]
11. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
[TBL] [Abstract][Full Text] [Related]
12. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma.
Rivera E; Arrieta O; Guevara P; Duarte-Rojo A; Sotelo J
Br J Cancer; 2001 Nov; 85(9):1396-9. PubMed ID: 11720480
[TBL] [Abstract][Full Text] [Related]
13. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
14. Coexpression of AT1 and AT2 receptors by human fibroblasts is associated with resistance to angiotensin II.
Galindo M; Santiago B; Palao G; Gutierrez-Cañas I; Ramirez JC; Pablos JL
Peptides; 2005 Sep; 26(9):1647-53. PubMed ID: 16112405
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Bequet-Romero M; Ayala M; Acevedo BE; Rodríguez EG; Ocejo OL; Torrens I; Gavilondo JV
Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
[TBL] [Abstract][Full Text] [Related]
16. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
Shiose S; Sakamoto T; Yoshikawa H; Hata Y; Kawano Y; Ishibashi T; Inomata H; Takayama K; Ueno H
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2395-403. PubMed ID: 10937546
[TBL] [Abstract][Full Text] [Related]
18. AT1 receptors and the actin cytoskeleton during angiotensin II treatment.
Bertels IM; Gontijo JA; Figueiredo JF
J Nephrol; 2007; 20(1):29-35. PubMed ID: 17347970
[TBL] [Abstract][Full Text] [Related]
19. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression.
Ohnuma Y; Toda M; Fujita M; Hosono K; Suzuki T; Ogawa Y; Amano H; Kitasato H; Hayakawa K; Majima M
Biomed Pharmacother; 2009 Feb; 63(2):136-45. PubMed ID: 18691848
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production.
Konopka TE; Barker JE; Bamford TL; Guida E; Anderson RL; Stewart AG
Cancer Res; 2001 Apr; 61(7):3182-7. PubMed ID: 11306506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
